Match!
Ricardo Dent
Amgen
60Publications
13H-index
907Citations
Publications 60
Newest
#1Ulrich LaufsH-Index: 68
#2Ricardo Dent (Amgen)H-Index: 13
Last.M. John Chapman (NIH: National Institutes of Health)H-Index: 78
view all 6 authors...
#1Matthew Mefford (UAB: University of Alabama at Birmingham)H-Index: 3
#2Gabriel S. Tajeu (TU: Temple University)H-Index: 9
Last.Paul Muntner (UAB: University of Alabama at Birmingham)H-Index: 72
view all 10 authors...
Guidelines recommend attempting to reinitiate statins in patients who discontinue treatment. Previous experiences while taking a statin, including side effects, may reduce a patient’s willingness to reinitiate treatment. We determined the percentage of adults who are willing to reinitiate statin therapy after treatment discontinuation. Factors associated with willingness to reinitiate a statin were also examined. A statin questionnaire was administered and study examination conducted in black an...
#1Leslie Cho (Cleveland Clinic)H-Index: 24
#2Ricardo Dent (Amgen)H-Index: 13
Last.Robert S. Rosenson (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 59
view all 9 authors...
Purpose Evolocumab reduced low-density lipoprotein cholesterol (LDL-C) in 12-week trials in statin-intolerant patients (GAUSS-1 and GAUSS-2); however, the persistence of efficacy during longer-term treatment is unknown. This subset analysis of the open-label extension studies (OSLER-1 and OSLER-2) aimed to evaluate the safety and efficacy of evolocumab up to 2 years in statin-intolerant patients.
#1John N. Booth (UAB: University of Alabama at Birmingham)H-Index: 16
#2Lisandro D. Colantonio (UAB: University of Alabama at Birmingham)H-Index: 16
Last.Keri L. Monda (Amgen)H-Index: 31
view all 12 authors...
Background Contact with the healthcare system represents an opportunity for individuals who discontinue statins to re‐initiate treatment. To help identify opportunities for healthcare providers to emphasize the risk‐lowering benefits accrued through restarting statins, we determined the types of healthcare utilization associated with statin re‐initiation among patients with history of a myocardial infarction. Methods and Results Medicare beneficiaries with a statin pharmacy fill claim within 30 ...
#1G. Kees HovinghH-Index: 59
#2Frederick J. Raal (University of the Witwatersrand)H-Index: 44
Last.David R. Sullivan (RPA: Royal Prince Alfred Hospital)H-Index: 45
view all 10 authors...
Background Evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9, is safe and effective when dosed biweekly (Q2W) or monthly (QM) in patients with heterozygous familial hypercholesterolemia (HeFH) as demonstrated in two 12-week trials: Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD; phase 2) and RUTHERFORD-2 (phase 3). Objective The objective of the study was to evaluate long-term efficacy,...
Background— Although the benefits of statins accrue over time, treatment discontinuation is common. Examining the patterns of statin discontinuation, reinitiation, and persistence after reinitiation among Medicare beneficiaries after hospital discharge for a myocardial infarction may help increase statin use in high-risk patients. Methods and Results— Medicare beneficiaries with a statin fill claim within 30 days after hospital discharge for myocardial infarction in 2007 to 2012 (n=158 795) were...
#1Peter P. Toth (Johns Hopkins University)H-Index: 38
#2Gillian Worthy (Amgen)H-Index: 3
Last.Carol A. ForbesH-Index: 9
view all 14 authors...
Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction. Methods and Results We conducted a systematic review and network meta‐analysis of randomized trials of lipid‐lowering therapies from database inception through August 2016 (45 058 records retrieved). We found 69 trials of lipid‐lowering therapies that...
#1Ivan Pećin (University Hospital Centre Zagreb)H-Index: 8
#2Merel L. HartgersH-Index: 5
Last.Željko Reiner (University Hospital Centre Zagreb)H-Index: 47
view all 5 authors...
Familial hypercholesterolaemia is an autosomal dominant inherited disorder characterised by elevated low-density lipoprotein cholesterol levels and consequently an increased risk of atherosclerotic cardiovascular disease (ASCVD). Familial hypercholesterolaemia is relatively common, but is often underdiagnosed and undertreated. Cardiologists are likely to encounter many individuals with familial hypercholesterolaemia; however, patients presenting with premature ASCVD are rarely screened for famil...
#1Franck Boccara (University of Paris)H-Index: 22
#2Ricardo Dent (Esperion Therapeutics Inc.)H-Index: 13
Last.P. Valensi (Nord University)H-Index: 43
view all 4 authors...
Suboptimal drug adherence represents a major challenge to effective primary and secondary prevention of cardiovascular disease. While adherence is influenced by multiple considerations, polypharmacy and dosing frequency appear to be rate-limiting factors in patient satisfaction and subsequent adherence. The cardiovascular and metabolic therapeutic areas have recently benefited from a number of advances in drug therapy, in particular protease proprotein convertase subtilisin/kexin type 9 (PCSK9) ...
#1Olivier S. DescampsH-Index: 24
#2Uwe Fraass (Amgen)H-Index: 3
Last.Ioanna Gouni-Berthold (University of Cologne)H-Index: 30
view all 5 authors...
SummaryObjectives To put data from our recent systematic review of phase 3 studies of anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies into the context of clinical practice. Methods Data from studies previously identified by a systematic review of phase 3 studies of alirocumab and evolocumab and additional references from non-systematic literature searches were used. We evaluated the hypothetical cardiovascular (CV) benefit in cases of typical patients in whom anti-PCSK9 ant...
123456